Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer

Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3…